Bogdanovski K., et al. (2018). High-Dose Inhaled Nitric Oxide as a Potential Therapy Against Mycobacterium Abscessus Lung Infection in Cystic Fibrosis. 3rd World Bronchiectasis Conference, Chronic Obstr Pulm Dis. 2018; 5(4): 302-323.

Olivier K.N., et al. (2018). Treatment of refractory mycobacterium abscessus lung infection with inhaled intermittent nitric oxide. 3rd World Bronchiectasis Conference, Chronic Obstr Pulm Dis. 2018; 5(4): 302-323.

Ghaffari, A. et al. (2018). High-dose nitric oxide as a potential new therapeutic agent against Mycobacterium abscessus. European Respiratory Journal 52: Suppl. 62, PA5463.

Goldbart, A., et al. (2018). A phase-III multicenter, randomized, double-blind, controlled trial of high-dose inhaled nitric oxide in infants with acute bronchiolitis. European Respiratory Journal 52: PA4642.

Bogdanovski K., et al. (2018). High-dose inhaled nitric oxide as a potential therapy against mycobacterium abscessus lung infection in cystic fibrosis. Pediatric Pulmonology, 52(S2): S1-S481

Yaacoby-Bianu, K., et al. (2018). Compassionate Nitric Oxide Adjuvant Treatment of Persistent Mycobacterium Infection in Cystic Fibrosis Patients. Pediatr Infect Dis J. 2018; 37(4):336-338.

Miller CC. et al., (2012). A phase I clinical study of inhaled nitric oxide in healthy adults. Journal of Cystic Fibrosis, 11:324-331

Miller CC, et al. (2007). Innate protection of Mycobacterium smegmatis against the antimicrobial activity of nitric oxide is provided by mycothiol. Antimicrob Agents Chemother. 2007 Sep;51(9):3364-6. Epub 2007 Jul 16

Ghaffari, A., et al. (2006). Potential application of gaseous nitric oxide as a topical antimicrobial agent. Nitric Oxide 14: 21-29

McMullin BB, et al. (2005). The antimicrobial effect of nitric oxide on the bacteria that cause nosocomial pneumonia in mechanically ventilated patients in the intensive care unit. Respir Care. 2005 Nov;50(11):1451-6.

• « Previous
• 1
• 2
• 3
• Next »